Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.72 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.67 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.67 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.67 |
| ▸ | ACE | P12821 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | FAP | Q12884 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361968 | 1.00 | DPP4 (0.72) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL30535978 | 1.00 | DPP4 (0.72) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL1509255 | 1.00 | DPP4 (0.72) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2162356 | 0.94 | DPP4 (0.67) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL14982915 | 0.94 | DPP4 (0.67) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2554245 | 0.92 | DPP4 (0.65) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL12285638 | 0.92 | DPP4 (0.71) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL1509250 | 0.91 | DPP4 (0.68) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2554221 | 0.91 | DPP4 (0.63) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2552198 | 0.91 | DPP4 (0.72) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409912-B2 | Process for the preparation of sitagliptin phosphate | CADILA HEALTHCARE LIMITED (IN) | 2016-08-09 | — | — | US | claimed |
| US-20150087834-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN PHOSPHATE | CADILA HEALTHCARE LIMITED (IN) | 2015-03-26 | — | — | US | claimed |
| EP-4469459-B1 | PROCESS FOR PREPARING CRYSTALLINE SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE | ZAKL FARMACEUTYCZNE POLPHARMA S A (PL) | 2026-01-21 | — | — | EP | disclosed |
| EP-4469459-A1 | PROCESS FOR PREPARING CRYSTALLINE SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE | Zaklady Farmaceutyczne Polpharma S.A. (PL) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023139276-A1 | PROCESS FOR PREPARING CRYSTALLINE SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2023-07-27 | — | — | WO | disclosed |
| CN-113979896-A | Sitagliptin impurity I and preparation method thereof | 浙江永太手心医药科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3811930-A1 | ORAL GLIPTIN COMPOSITIONS AND METHOD FOR PREPARATION THEREOF | Authenda Pharmaceuticals AG (CH) | 2021-04-28 | — | — | EP | disclosed |
| US-20200206221-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-07-02 | — | — | US | disclosed |
| US-9409912-B2 | Process for the preparation of sitagliptin phosphate | CADILA HEALTHCARE LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-20150087834-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN PHOSPHATE | CADILA HEALTHCARE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| WO-2010097420-A1 | PROCESS FOR THE PREPARATION OF A CHIRAL BETA AMINOACID DERIVATIVE AND INTERMEDIATES THEREOF | Esteve Química, S.A. (ES) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206221-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
| US-20150087834-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN PHOSPHATE | DPP4, DPP9, SI | DPP4 1/4885DPP8 9/4885DPP9 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.